Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110 HER2 ADC Biosimilar
Formosa Pharmaceuticals files a clinical trial application for TSY-110, a HER2-targeting Antibody Drug Conjugate (ADC) biosimilar positioned as a potential alternative to Roche’s Kadcyla.
Erick Co | 01/09/2026 | By News Bureau
Exclusive licensing deal grants Arrotex rights to market clobetasol propionate ophthalmic suspension for post-surgical ocular inflammation and pain, expanding Formosa’s footprint in Oceania.
Erick Co | 23/02/2026 | By News Bureau | 187
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy